Related Experiment Video
Updated: Jul 30, 2025
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference
Andrew Wang1, James Liu2, Jeffrey J Pu3
1Pennsylvania State University, University Park, PA, 16802, USA.
Abstract:
Myelofibrosis (MF) is a disorder characterized by the proliferation of myeloid precursors, commonly due to overactive JAK signaling. The discovery of the JAK2V617F mutation and subsequent development of JAK inhibitors (JAKi) results in reduced spleen size, improved symptom, and enhanced survival in MF patients. However, there are unmet needs of additional novel targeted therapies for this incurable disease due to the limited utility of first-generation JAKis, which are associated with dose-limiting cytopenia and disease recurrence. New targeted treatment strategies for MF are on the horizon. We are here to discuss the latest clinical research findings presented in the 2022 ASH Annual Meeting.
Insights
Myelofibrosis treatments targeting JAK signaling improve symptoms but have limitations. New targeted therapies are emerging to address unmet needs in this incurable blood cancer.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Myelofibrosis (MF) is a clonal hematopoietic stem cell disorder.
- Overactive Janus kinase (JAK) signaling, particularly JAK2V617F mutation, drives MF pathogenesis.
- Current JAK inhibitors (JAKi) offer clinical benefits but have limitations like cytopenia and disease recurrence.
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Differentiation of Common Myeloid Progenitor Cells

